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Inadequate micronutrient intakes are relatively common in low- and middle-income countries (LMICs), espe-
cially among pregnant women, who have increased micronutrient requirements. This can lead to an increase in
adverse pregnancy and birth outcomes. This review presents the conclusions of a task force that set out to assess
the prevalence of inadequate micronutrient intakes and adverse birth outcomes in LMICs; the data from trials
comparing multiple micronutrient supplements (MMS) that contain iron and folic acid (IFA) with IFA supple-
ments alone; the risks of reaching the upper intake levels with MMS; and the cost-effectiveness of MMS compared
with IFA. Recent meta-analyses demonstrate that MMS can reduce the risks of preterm birth, low birth weight,
and small for gestational age in comparison with IFA alone. An individual-participant data meta-analysis also
revealed even greater benefits for anemic and underweight women and female infants. Importantly, there was no
increased risk of harm for the pregnant women or their infants with MMS. These data suggest that countries with
inadequate micronutrient intakes should consider supplementing pregnant women with MMS as a cost-effective
method to reduce the risk of adverse birth outcomes.
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Introduction
Adequate intakes of essential vitamins and min-
erals (micronutrients) are required during preg-
nancy for maternal health and fetal development.
Insufficient nutrient intakes before and during
pregnancy, combined with increased metabolic
demands during pregnancy, can result in indi-
viduals suffering from one or more micronutri-
ent deficiencies, especially in low- and middle-
income countries (LMICs). Supplementation with
multiple micronutrient supplements (MMS) that
include iron and folic acid (IFA) during pregnancy
is practiced in some countries, including the United
States and South Africa, to increase micronutrient
intakes and improve pregnancy outcomes.1,2 How-
ever, IFA supplementation is currently the recom-
mended standard of care for pregnant women in
many countries.
Two recent reviews, a Cochrane systematic
review and meta-analysis and an individual-
participant data (IPD) meta-analysis, have assessed
trials that compared the use of MMS with IFA
in pregnant women and were predominantly
conducted in LMICs.3,4 Both reviews reported
improved pregnancy and birth outcomes among
women receivingMMS, including a lower incidence
of low birth weight (LBW) and small for gestational
age (SGA) births as compared with women receiv-
ing IFA supplementation. An earlier (2015) version
of the Cochrane Review informed the 2016 World
Health Organization (WHO) Guidelines for Ante-
natal Care (ANC), while the IPD meta-analysis was
published after the guideline committee meetings.
The current WHO ANC Guidelines do not rec-
ommend that MMS replace IFA as routine standard
of care because of “… some evidence of risk, and
some important gaps in the evidence.”5 However,
the guidelines further comment “that policymakers
in populations with a high prevalence of nutritional
deficiencies might consider the benefits of multi-
ple micronutrient supplements on maternal health
to outweigh the disadvantages [such as cost], and
may choose to give multiple micronutrient supple-
ments that include iron and folic acid.” Yet, no fur-
ther guidance was provided regarding the contexts
where MMS may be warranted.
Two exceptions to this guideline are in emer-
gency settings and for pregnant women with active
tuberculosis (TB), where the risk of micronutri-
ent deficiencies is especially high in vulnerable
groups, including pregnant and lactating women.
To address these risks in emergency settings, the
WHO, UNICEF, and WFP issued a statement in
2007 recommending MMS for pregnant and lac-
tating women.6 The recommendation states that
MMS should be given in addition to IFA in settings
where IFA supplementation exists, even in the pres-
ence of fortified rations, and should continue for
the duration of the emergency. In the case of active
TB, WHO guidelines from 2013 mandate MMS for
pregnant and lactating women for nutritional care
and support for patients.7
This review is based on the conclusions of a
task force created to develop guidance for coun-
tries as they consider implementation of MMS as
a standard of care for pregnant women and to
assess the benefits and possible risks of antenatal
MMS use in LMICs. The task force, comprising 33
members from a variety of organizations, including
nongovernmental organizations, nonprofit organi-
zations, and academia, met in November 2017 and
April 2018 (see Appendix 1 for a full list of mem-
bers of the task force; online only). This work was
commissioned by the Bill & Melinda Gates Foun-
dation and organized by the New York Academy of
Sciences. As a direct outcome of the task force, the
objectives of the current review are to (1) review the
evidence on the burden of micronutrient deficien-
cies in women of reproductive age (WRA) and asso-
ciated adverse pregnancy outcomes; (2) update the
evidence base on the effects of MMS on pregnancy
outcomes; (3) assess the costs and cost-effectiveness
of shifting from IFA to MMS during pregnancy;
and (4) provide indicators based on the updated
evidence base that might be considered by govern-
ments deciding whether IFA or MMS is the most
appropriate supplement for their contexts.
The role of micronutrients in pregnancy
As discussed in a recent detailed review, the impor-
tance of several individual micronutrients during
critical periods of human development is reflected
in the evidence from human trials and observa-
tional data.8 Much of our understanding of the
mechanisms by which micronutrients affect criti-
cal early pregnancy events is derived from animal
models. Micronutrients are known to affect con-
ceptus development from early gestation onward,
including implantation and vascularization of the
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placenta, offspring morphogenesis, organogenesis,
and neurological development.8
Specifically, zinc, folate, niacin, riboflavin, and
vitamins B6 and B12 are considered particularly
important in early gestation as these micronutri-
ents are involved in one-carbon metabolism, which
is essential for cell proliferation, growth, and pro-
tein synthesis in the earliest stages of gestation.8,9
These micronutrients are also known to play a
role in the rapid demethylation of maternal and
paternal genomes immediately following concep-
tion, as well as the sustained remethylation of
the fetal genome during gestation. Zinc and vita-
min D also contribute to placental development
and function. Throughout gestation iron, folate,
zinc, niacin, and vitamins B6 and A support the
organogenesis and development of the fetal cen-
tral nervous system, while iodine is important in
early brain development.8,9 A recent study demon-
strated that mitochondrial efficiency was greater
for women receiving MMS compared with IFA.65
Thus,micronutrient deficiencies can result in awide
variety of birth defects and adverse pregnancy out-
comes, including LBW, which is caused by either
intrauterine growth restriction (IUGR) or preterm
birth.
Micronutrient deficiencies during
pregnancy
Monotonous, nutrient-poor diets are common
among women in LMICs, and the increased nutri-
ent needs of pregnancy further raise the likeli-
hood that pregnant women in settings with low
dietary diversity or food insecurity will experi-
ence inadequate intakes of micronutrients as well
as energy, essential amino acids, and fatty acids.
While the focus of this review is on micronutri-
ent nutrition during pregnancy, it is important to
acknowledge the coexistence of protein and energy
deficiencies along with micronutrient deficiencies,
which may further exacerbate the adverse effects
on pregnancy outcomes. In addition to IFA supple-
ments, the WHO ANC Guidelines therefore make
a context-specific recommendation for balanced
energy and protein dietary supplementation for
pregnant women in undernourished populations to
reduce the risk of stillbirths and SGA neonates.10,11
Micronutrient deficiencies are prevalent among
pregnant and lactating women andWRA in LMICs,
although data are limited. A systematic review of
studies reporting on selected vitamin and min-
eral intakes among pregnant women in LMICs
Figure 1. Regional estimates of micronutrient deficiencies and anemia as reported in women of reproductive age. Black circles
are not representative (<3 countries). Data calculated from 52 national and regional surveys, published between 2013 and July
2017.66 Missing bars means no data were found for that micronutrient in the specific region.
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Figure 2. Prevalence of anemia (Hb < 120 g/L) by country among women of reproductive age in LMICs. Data calculated from
52 national and regional surveys, published between 2013 and July 2017.66
concluded that inadequate nutrient intakes from
poor diets were common, with mean/median folate
and iron intakes most frequently found to be below
the estimated average requirements, followed by
calcium and zinc.12 Estimates reported in 2013 by
Black et al. suggest that 19.2% of pregnant women
in LMICs had iron deficiency anemia (IDA) on the
basis of 2011 data, 15.3% were vitamin A deficient
(data from 1995 to 2005), and 17.3% were at risk
of zinc deficiency (based on inadequate zinc intakes
from 2005).13
An update of the Black et al. review,13 including
data from WRA in addition to data from pregnant
women, was performed for this task force by search-
ing for surveys published from 2013 until July 2017
in PubMed. The search strategy and number of arti-
cles identified are described in Appendix 2 (online
only). The percentage of deficiencies was used as
reported in the survey, even though cutoffs used
to define deficiencies varied among the studies and
surveys. Cutoffs used for each survey are described
in Appendix 3 (online only) for WRA. In general,
deficiencies of vitamin D, iodine, and zinc were
widespread in WRA (Fig. 1). On the basis of the
individual reported country prevalences, weighted
average regional (using WHO regions) prevalences
were calculated, if there were at least three country
estimates available for the particular micronutrient
deficiency. On average, 63.2% ofWRAwere vitamin
D deficient, 41.4% were zinc deficient, 31.2% were
anemic, and 22.7% were folate deficient. Iron defi-
ciency could not be estimated, but IDAwas reported
in some studies and was often less than half of all
anemia (Fig. 1). The prevalence of vitamin A defi-
ciency in WRA was 15.9% for all LMICs but var-
ied substantially between countries. For instance,
in Pakistan, 43.2% of all WRA were reported to be
vitamin A deficient,14 whereas the prevalence was
only 1.6% in Vietnam.15 Similarly, there was a high
variability in anemia prevalence among countries.
In Africa, estimates of anemia prevalence in WRA
ranged from 17.7% in Ethiopia16 to as high as 54.5%
in Congo17 (Fig. 2). It should be noted that although
many of the surveys are more than 10 years old and
updated data on micronutrient deficiencies among
women and children are needed, available evidence
indicates that multiple micronutrient deficiency is a
public health problem in most LMICs.
No regional estimates could be calculated for
micronutrient deficiencies in pregnantwomen,with
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Figure 3. Prevalence of anemia (Hb< 120 g/L) by country among pregnant women in LMICs. Data calculated from 21 national
and regional surveys and studies, from 2013 to July 2017.66
the exception of IDA and iodine, owing to a lack
of data. Overall, 31.6% of pregnant women in
LMICs were anemic, with particularly high preva-
lence inAfrica (48.3%) and South-East Asia (44.8%)
(Fig. 3). Cutoffs used for each survey in preg-
nancy are described in Appendix 4 (online only).
Assuming 50% of all anemia is caused by iron
deficiency, Black et al. estimated regional preva-
lences of IDA among pregnant women of 20.3%
in Africa and 19.8% in Southeast Asia. Using this
same assumption to estimate IDA, our estimates
in pregnant women based on the new review were
15.8% in all LMICs, with regional estimates in
Africa and Southeast Asia of 24.2% and 22.4%,
respectively.
The Iodine Global Network (IGN) provides
the most up-to-date estimates for prevalences of
insufficient iodine intakes and these data were
used for our review. In 2017, IGN estimated that
pregnant women in 40 countries had insufficient
iodine intakes (median urinary iodine concentra-
tion (mUIC) <150 µg/L), particularly in South
Asia, the Middle East, Europe, the United States,
and Australia. In contrast, pregnant women in
countries in Latin America, Southeast Asia, and
Southern Africa were estimated to have adequate
iodine intakes, which may partly reflect the success
of salt iodization programs in these countries.18 It
should be noted that not all data are nationally rep-
resentative, and in some cases IGN relies only on
subnational data to produce national estimates of
iodine intake.
Adverse pregnancy, maternal, and child
outcomes
Adverse pregnancy outcomes, including LBW,
preterm birth, SGA, perinatal mortality, and mater-
nal mortality, are common in LMICs and associ-
ated with maternal micronutrient malnutrition.8
In addition, micronutrient deficiencies have been
associated with other adverse maternal and child
outcomes, including maternal depression and
maternal and child cognitive impairment,19–22
premature rupture of membranes, insufficient ges-
tational weight gain, congenital anomalies, and
pre-eclampsia.23 Notably, stillbirth is difficult to
study in LMICs because it is often not reported as
10 Ann. N.Y. Acad. Sci. 1444 (2019) 6–21 © 2019 The Authors. Annals of the New York Academy of Sciences
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Table 1. Prevalence of adverse pregnancy and birth outcomes
Sub-Saharan Africa Asia Southeast Asia South Asia World
Preterm births (2014) (%)a 12.0 10.4 N/R N/R 10.6
SGA (2012) (%)b 16.5 N/R 21.6 34.2 19.3
LBW (2009–2013) (%)c 13.0 N/R N/R 28 16
Maternal mortality ratio (per 100,000 live births)d 546 N/R 62 182 216
Stillbirths (per 1000 total births)e 28.7 N/R 12.2 25.5 18.4
Neonatal mortality (per 1000 live births)f 27.7 N/R 13.5 27.6 18.6
aEstimated mean preterm birth rate defined as all live births before 37 weeks of completed weeks of gestation, whether singleton,
twin, or higher order multiples, divided by all live births in the population.67
bSGA, small for gestational age, defined as birth weight less than the 10th percentile for a specific completed gestational age by sex,
using the INTERGROWTH-21st standard; SGA rate defined as all termandpretermSGA, divided by all live births in the population.26
cLow birth weight defined as the number of live births weighing less than 2500 g divided by all live births in the population.24
dMaternal mortality is defined as the number of maternal deaths per 100,000 live births (maternal death = death of a women while
pregnant or within 42 days of termination of pregnancy, from any cause related to or aggravated by the pregnancy or its management);
2015 estimates.28
eStillbirth rate estimates are based on the late fetal death definition: 1000 g or more with an assumed equivalent of 28 weeks’ gestation
or more, or 35 cm or more; 2015 estimates per 1000 total births.29
fNeonatal mortality defined as deaths in the first 28 days of life per 1000 live births; 2016 estimates.30 N/R, not reported.
an adverse outcome, but it is also associated with
poor micronutrient status.
Overall, 16% of all live births in LMICs in 2014
were LBW (<2500 g) with South Asia carrying the
largest burden (28%).24 SGA, preterm, and both
preterm and SGA infants have an increased mor-
tality risk.25 On the basis of secondary analyses of
data from theChildHealth Epidemiology Reference
Group in 2012 in LMICs, an estimated 23.3 mil-
lion infants, or 19.3% of all live births, were SGA;
and an estimated 606,500 neonatal deaths, or 21.9%
of all neonatal deaths, were attributable to SGA.
SGA was defined as infants weighing <10th per-
centile of birth weight-for-gestational age and sex
according to the multiethnic, INTERGROWTH-
21st birthweight standard.26 SouthAsia also had the
highest prevalence of SGA (34% of all live births)
(Table 1).26
A 2018 review, assessing data fromNational Reg-
istries, Reproductive Health Surveys and published
studies, estimated that in 2014, 14.84million babies,
or 10.6% of live births, were born preterm world-
wide. More than 80% of preterm babies were born
in Asia (7.8 million, or 10.4% of live births) and
Sub-Saharan Africa (4.2 million, or 12.0% of live
births).27
While conditions related to IUGR are most
prevalent in South Asia, Sub-Saharan Africa
has the highest incidence of maternal mortal-
ity (546 per 100,000 live births), stillbirths (28.7
per 1000 total births), and neonatal mortality
(27.7 per 1000 live births) (Table 1).28–30 Data on
the prevalence of other adverse pregnancy out-
comes, including insufficient gestational weight
gain, macrosomia, pre-eclampsia, PROM, and
congenital abnormalities, are scarce and often
from small, local sources, which may be prone to
under-reporting.
Poor maternal micronutrient status has also been
associated with poor longer term health and devel-
opment outcomes for the infant/child,31,32 but the
evidence of the impact of MMS on development is
limited and exposure to other environmental risk
factors later in life confounds the associations.33
Recent evidence, from a maternal micronutrient
supplementation trial in Indonesia,68 suggests that
children from mothers who had received multi-
ple micronutrients during pregnancy had better
cognitive development across multiple domains at
3–4 years of age, especially children of malnour-
ished and anemic women, and improved procedu-
ral memory at 9–12 years of age. The 9- to 12-year
follow-up study also found higher general intellec-
tual ability among children of anemic mothers who
received multiple micronutrients during pregnancy
comparedwith the IFA group.22 Poor child develop-
ment has also been indirectly associated with poor
micronutrient status during pregnancy, since chil-
dren born LBW are at higher risk of developmental
delays later in life.34
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Interventions to improve micronutrient
nutrition in pregnant women and to reduce
adverse pregnancy and birth outcomes
To address micronutrient malnutrition in the
general population, WHO and the Food and Agri-
cultural Organization of the United Nations have
identified four complementary strategies: (1) nutri-
tion education leading to increased diversity and
quality of diets; (2) food fortification and biofor-
tification; (3) disease control measures; and (4)
supplementation (currently only routine iron-folic
acid is recommended in pregnancy, along with
context-specific recommendations for protein-
energy, calcium, vitamin A, and zinc).35 Healthy
eating is also formally recommended for pregnant
women. However, it is generally a challenge to
cover all of their nutrient needs with local foods
because even optimized local diets may be insuffi-
cient to meet the increased nutrient needs during
gestation.8
Revisiting the evidence base on the effect
of multiple-micronutrient supplements in
pregnancy
Overview of the 2019 Cochrane Review
The 2019 Cochrane Review (updated from 2015) on
the use of MMS during pregnancy evaluated the
effects of MMS as compared with IFA on pregnancy
outcomes; the 2015 Cochrane Review was used to
inform the development of the WHO ANC Guide-
lines on MMS in pregnancy.3,5 A total of 20 tri-
als, which included a total of 141,849 women, that
met the inclusion criteria and reported outcomes
of interest to the review were identified. Nineteen
of 20 trials were carried out in LMICs using MMS
that included IFA compared with iron with or with-
out folic acid; 14 of these trials were considered in
the WHO ANC Guidelines. The Cochrane review-
ers note that at the time of their literature search
(February 23, 2018), there was one trial awaiting
classification,36 as well as four ongoing trials that
could not be included.37–40
The analyses in the Cochrane Review demon-
strated that overall MMS resulted in a 12% reduc-
tion in LBW (RR: 0.88; 95% CI: 0.85–0.91) and
a 8% reduction in SGA births (RR: 0.92; 95%
CI: 0.88–0.97), compared with IFA supplemen-
tation, with high and moderate quality evidence
(based on GRADE criteria),41 respectively.3 There
were no significant differences identified for other
maternal or pregnancy outcomes assessed, includ-
ing preterm birth, stillbirth, maternal anemia in
the third trimester, miscarriage, maternal mortal-
ity, perinatal mortality, neonatal mortality, or risk
of delivery by caesarean section when MMS was
compared with supplementation with iron or with-
out folic acid. A summary of these analyses is pre-
sented in Table 2, alongside the results from the IPD
meta-analysis for comparison, which is discussed in
more detail below.3,4 However, it should be noted
that the IPDwas based on voluntary participation of
the trial’s investigators and was primarily aimed at
conducting subgroup analyses, while the Cochrane
Reviewwas focused on the overall effects of all avail-
able trials.
To evaluate the possible effect modification, the
Cochrane Review performed several population-
level subgroup analyses, including analyses that
stratify, on the basis of the study-specific aver-
ages of maternal body mass index (BMI), mater-
nal height, timing of supplementation, and the iron
dose. Among the 10 trials in which the average
maternal BMI was at least 20 kg/m2, there was evi-
dence of a lower incidence of SGA among thosewho
received MMS compared with IFA, while there was
no evidence of a difference among the three trials
where the mean BMI was less than 20 kg/m2 (P
value for subgroup differences = 0.001). Similarly,
among the six trials in which the average maternal
height was at least 154.9 cm, MMS was associated
with a reduction in SGA, while no effect was appar-
ent in the eight trials in which the average maternal
height was less than 154.9 cm (P value for subgroup
differences <0.0001). Thus, while the review sug-
gests thatMMS reduces the risk of SGA, the review-
ers caution that this effect was only observed in pop-
ulations with better nutritional status, as defined by
a height of at least 154.9 cm or a BMI of at least 20
kg/m2. However, among trials in which the average
maternal BMI was less than 20 kg/m2, those receiv-
ingMMS had a lower rate of preterm birth, whereas
no difference for preterm birthwas observed among
trials in which the average BMI was greater than
or equal to 20 kg/m2 (P value for subgroup differ-
ences <0.0001). The authors found no subgroup
differences by the dose of iron with regard to
preterm birth, SGA, or perinatal mortality, on the
basis of the 15 studies included in this subgroup
analysis.
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Table 2. Overall effects of MMS on birth outcomes in comparison with iron, with or without folic acid in LMICs
based on the Cochrane Review and an IPD meta-analysis (RR, 95% CI)
Cochrane Review3 IPD meta-analysis4
(15 RCTs) (17 RCTs)
Relative risks Relative risks
Outcome Random effects Random effects Fixed effects
SGA (<10th percentile) 0.92 (0.88–0.97)a 0.94 (0.90–0.98)b 0.97 (0.96–0.99)b
LBW (<2500 g) 0.88 (0.85–0.91) 0.86 (0.81–0.92) 0.88 (0.85–0.90)
VLBW (<2000 g) Not reported Not reported 0.78 (0.72–0.85)
Preterm birth (<37 weeks) 0.96 (0.90–1.03) 0.93 (0.97–0.98) 0.92 (0.88–0.95)
Very preterm birth (<34 weeks) Not reported Not reported 0.87 (0.79–0.95)
LGA (>90th percentile Oken) Not reported 1.04 (0.92–1.18) 1.05 (0.95–1.15)
LGA (>90th percentile INTERGROWTH) Not reported Not reported 1.11 (1.04–1.19)
Stillbirth 0.95 (0.86–1.04) 0.97 (0.85–1.11) 0.92 (0.86–0.99)
Neonatal mortality (≤28 days) 1.00 (0.89–1.12) 0.99 (0.89–1.09) 0.98 (0.90–1.05)
Infant mortality (≤365 days) Not reported 0.97 (0.88–1.06) 0.97 (0.88–1.06)
aSGA defined by authors of trials.
bSGA defined by the INTERGROWTH-21 standard.
RCTs, randomized controlled trials.
Overview of the 2017 IPD meta-analysis
Smith et al. obtained IPD from 17 randomized con-
trolled trials—including 112,952 pregnancies—that
compared the use of MMS, which included IFA,
versus IFA alone.4 Fifteen of these trials were also
included in the 2019 Cochrane Review. The IPD
meta-analysis found that MMS reduces the risk
of stillbirth (on the basis of fixed effects analy-
sis), very LBW (VLBW), LBW, early preterm birth,
preterm birth, and SGA (by INTERGROWTH-
21 standards and Oken reference) when compared
with IFA. This is in contrast to theCochrane Review,
which only found the evidence of effects of MMS
on LBW and SGA. Table 2 contains a summary
of these results in comparison to the results from
the Cochrane Review. In addition, Smith et al.
also found the evidence of increased risk of large
for gestational age (LGA) (by Intergrowth stan-
dards but not by Oken reference), which was not
examined in the Cochrane Review. While this may
raise concerns about increased risk of obstructed
labor/asphyxiation, the authors noted that MMS
was not associated with increased risk of still-
birth or mortality at any time point, including
among women with short stature (less than 150
cm), who are more likely to be at risk of obstructed
labor.
Twenty-six subgroup analyses were conducted
with numerous outcomes in the IPD meta-analysis
to identify individual characteristics that may mod-
ify the effect of MMS as compared with IFA alone.
These analyses (summarized in Box 1) revealed the
evidence of larger benefits of MMS among women
who were anemic (defined as hemoglobin <110
g/L for pregnant women), were underweight (BMI
<18.5 kg/m2), started supplementation before 20
weeks of gestation, had higher supplement adher-
ence (>95%), were carrying a female fetus, and had
a skilled birth attendant.
Revisiting the risks and concerns of
antenatal MMS
Risk of neonatal mortality
The WHO ANC Guidelines state that a source of
concern in regard to recommending MMS was the
potential risk of increased neonatalmortality.42 This
concern arose from a meta-analysis of a subset of
trials performed for the WHO guidelines review
(Fig. 10b of the subgroup analyses grouping trials
according to the dose of iron in the control group
in the WHO ANC Guidelines Web Supplement).
The trials included in this subgroup analysis were
(1) trials using MMS (containing any dose of IFA)
compared with an IFA control group that received
60 mg of iron and 400 µg of folic acid and (2) tri-
als using MMS (containing any dose of IFA) com-
pared with an IFA control group that received 30
mg of iron and 400 µg of folic acid.42 Among trials
using a 60 mg iron plus 400 µg of folic acid in the
control group, the relative risk of neonatal mortality
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Box 1. Summary of effect modifiers4
 The effects of MMS compared with IFA appeared greater among anemic pregnant women than
nonanemic women for LBW (19% reduction for anemic women versus 9% reduction for nonanemic
women; P value for heterogeneity 0.049), SGA (8% versus 1% reduction; P value for heterogeneity 0.03),
and 6-month infant mortality (29% versus 7% reduction; P value for heterogeneity 0.04).
 The effects of MMS compared with IFA appeared greater among underweight pregnant women than
nonunderweight women in reducing the risk of preterm birth (16% for underweight women versus 6%
for nonunderweight women; P value for heterogeneity 0.01).
 The effects of maternal MMS compared with IFA appeared greater among female infants than male
infants with respect to reducing the risk of neonatal mortality (15% reduction for females versus 6%
increase for males; P value for heterogeneity 0.007), 6-month mortality (15% reduction for females
versus 2% reduction for males; P value 0.06), and infant mortality (13% reduction for females versus 5%
increase for males; P value for heterogeneity 0.04).
 The effects of MMS compared with IFA appeared greater among women who started supplementation
before 20 weeks of gestation than those who started after 20 weeks in reducing the risk of preterm birth
(11% reduction before 20 weeks versus no change after 20 weeks; P value for heterogeneity 0.03).
 The effects of MMS compared with IFA appeared greater among women who started supplementation
after 20 weeks of gestation than those who started before 20 weeks in reducing the risk of stillbirth (19%
reduction after 20 weeks versus 3% reduction before 20 weeks; P value for heterogeneity 0.05).
 The effects of MMS compared with IFA appeared greater when adherence was greater than or equal to
95% versus less than 95% for survival and birth outcomes, specifically for neonatal mortality (12%
reduction for greater than or equal to 95% adherence versus 5% increase for less than 95% adherence; P
value for heterogeneity 0.05) and infant mortality (15% reduction versus 6% increase; P value for
heterogeneity 0.02).
 MMS did not significantly increase the risk of stillbirth, neonatal, 6-month, or infant mortality in any of
the 26 subgroups analyzed compared with IFA.
was 1.22 (0.95, 1.57) for those receivingMMSversus
IFA in the subset of discordant iron doses.42 How-
ever, in these calculations, the effect estimate used
for the Bhutta 2009 trial was incorrectly quoted,
using a risk ratio of 0.97 (0.66, 1.45), which should
have been 1.44 (0.99, 2.18).43 A recent reanalysis of
these data, performed by Sudfeld and Smith, used
the corrected risk ratio estimates of the Bhutta 2009
trial and five additional trials that provided 60 mg
of iron in the IFA group.44 These five additional tri-
als include the MINIMat trial group using a 60 mg
iron dose (with 400 µg of folic acid) in the control
arm,45 two trials with 60 mg of iron but only 250µg
of folic acid in the control group,46,47 and two newer
trials that were not previously available (lipid-based
supplement arms excluded).48,49 With the inclusion
of these studies and the updated risk ratio for the
Bhutta trial, the risk ratio for neonatal mortality
of MMS compared with IFA was 1.05 (0.85, 1.30)
(Fig. 4).
Risk of reaching the UL
The United Nations International Multi-
ple Micronutrient Antenatal Preparation, or
UNIMMAP, is the supplement most commonly
used in MMS in trials with pregnant women. It
provides 15 vitamins and minerals, including IFA.
The composition of UNIMMAP largely reflects rec-
ommended dietary allowances (RDAs) or adequate
intakes (AIs) (as of 1998) for each included vitamin
and mineral, with some slightly lower dosages
for folic acid and iodine.50,51 Gernand modeled
the impact of supplementation with UNIMMAP
on the micronutrient intakes of pregnant women
consuming a nutrient-rich, diverse diet that meets
the dietary intake recommendations from both
WHO52 and the Institute of Medicine53 and found
very little risk of excessive intakes (i.e., exceeding
the upper level (UL) of recommended nutrient
intakes). When UNIMMAP was provided along
with a nutrient-rich diet, intakes of iron, niacin, and
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Figure 4. Forest plot for the effect of MMS versus IFA (with 60 mg of iron and any dose of folic acid) in the control group on
neonatal mortality. This includes all available trials that included a 60 mg iron control group. Reproduced from Sudfeld and
Smith.44
folic acid reached or slightly exceeded the UL; but
these were unlikely to result in significant adverse
effects.54 More detailed information on the risk of
exceeding the UL with MMS can also be found in
Gernand.54 In regard to iron intake, the current
WHO recommendation is 30–60 mg in pregnancy;
however, the U.S. Institute of Medicine set the UL
at 45 mg, suggesting that 30 mg may have a better
safety margin than 60 mg.51
Side effects and adherence data for MMS
and IFA
Side effects and adherence to supplementation are
important considerations for any supplementation
program, as these could influence the effectiveness
of the intervention. Unfortunately, these outcomes
are not consistently reported inmany trials compar-
ingMMS and IFA, and differences in how outcomes
are reported (e.g., number of timesmedical care was
sought versus self-reporting of specific symptoms)
make it difficult to compare findings. Nonetheless,
there does not appear to be any important difference
in side effects between IFA and MMS in six of the
seven trials that reported on side effects.43,55–59 In a
seventh trial, more women reported vomiting in the
MMS group compared with the IFA group (MMS,
11.6%; IFA (60 mg iron), 6.9% (P= 0.002); and IFA
(30 mg iron), 7.1% (P = 0.003)), but no evidence of
differences was noted for any other side effect.45
Similarly, there were large differences in the
methods used to assess adherence to the sup-
plements (e.g., pills missing from bottles or self-
reported dosing), and not all studies reported on
adherence. Despite these inconsistencies in report-
ing, differences in adherence rates between the
IFA and MMS groups were generally very small,
with no more than a 2% difference between the
intervention groups in 10 trials that reported on
adherence.43,48,49,55–60 Importantly, there were no
trends toward better adherence to one supplement
versus the other. On the basis of these available data,
there appears to be no evidence of differences in
self-reported side effects or adherence between IFA
and MMS.
A complicating factor with regard to analyzing
data from trials that compared MMS with IFA is
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that the iron dose in the IFA control group was
often greater than that in the MMS. For example,
UNIMMAP was the most commonly used multiple
micronutrient supplement formulation (eight tri-
als), and it contains 30 mg of iron. In most of those
eight trials, it was compared with an IFA supple-
ment containing 60 mg of iron. Strictly speaking,
this precludes knowing whether the effects of the
MMSwere attributable to the lower dose of iron ver-
sus the addition of other nutrients. The iron content
inUNIMMAPwas set at 30mg to be a single RDA51
for pregnant women (27 mg is the current RDA61)
similar to all other nutrients, and to avoid the risk of
side effects because the presence of other micronu-
trients (e.g., vitamin A, vitamin C, and riboflavin)
was expected to improve the absorption or utiliza-
tion of iron compared with the iron in IFA alone.
Unfortunately, there are very few trials that com-
pared the effect on birth outcomes by dose of iron
supplementation. TheMINIMat trial in Bangladesh
is the only study that used two IFA arms, one con-
taining 60 mg iron and the other 30 mg, plus a mul-
tiple micronutrient supplement arm with 30 mg of
iron. When comparing the two iron doses within
the IFA treatment arms, there was no evidence of
differences between 30 and 60 mg iron with regard
to birthweight, anemia at 30 weeks’ gestation, still-
birth, early neonatal, perinatal, neonatal, and infant
mortality rates. However, the study was powered for
detecting differences in anemia and birthweight, not
mortality.45
Cost-effectiveness
A narrowly focused cost-effectiveness analysis of
switching from IFA to MMS (single-year, complete
and immediate switching) has been performed for
two countries, Bangladesh and Burkina Faso.62 For
this analysis, they assumed a dose of 180 tablets
per pregnant woman, which would cost an addi-
tional∼US$0.88 for each pregnancy, and estimated
the current coverage of IFA programs in each coun-
try. The results of the IPD meta-analysis were used
for the birth outcome data, using the overall effects
and subgroup analyses.4 Making the switch toMMS
in Bangladesh, where coverage of the national IFA
program is estimated to be ∼50%, would cost
approximately $39 per case of LBW averted, $85
per case of preterm birth averted, $62–$104 per
case of SGA averted (INTERGROWTH-21st and
Oken standards, respectively), and $239 per case of
infantmortality averted. Combining the years of life
lost and disability-adjusted life years (DALY) from
sequelae of preterm birth, the cost per disability-
adjusted life year averted was $13.25 for calcula-
tions using overall effects and $4.60 for calculations
accounting for different effects among population
subgroups from the IPDmeta-analysis ofMMS ver-
sus IFA on mortality and birth outcomes.4
In the case of Burkina Faso, where ∼10% of
women reported taking at least 180 IFA tablets dur-
ing their last pregnancy, authors estimated the fol-
lowing approximate costs: $58 per case of LBW
averted, $102 per case of preterm birth averted,
$91–$152 per case of SGA averted (INTERG-
ROWTH-21st and Oken standards, respectively),
and $148 per case of infant mortality averted. Com-
bining the years of life lost and disability-adjusted
life years from sequelae of preterm birth, the cost
per DALY averted was $15.21 for calculations using
overall effects and $3.56 for calculations accounting
for effect modification in the effects of MMS versus
IFA on mortality and birth outcomes. Assuming a
cost differential of $2 per covered pregnancy (i.e.,
$3 per dose of the UNIMMAP formulation and $1
per dose of IFA; WHO, 2016) would approximately
double these cost-effectiveness estimates (increase
of $2/$0.88 = ∼2.3).
Similar to existing IFA programs, programmatic
inefficiencies and low adherence will increase the
cost per outcome averted and dramatically so under
some sets of assumptions. Nonetheless, the values
reported above for multiple micronutrient supple-
mentation are still likely to compare favorably to
those of more complex interventions to prevent
preterm birth and infant mortality, such as screen-
ing for and managing chronic disease among preg-
nant women.62 For example, pneumococcus and
rotavirus vaccines and mother’s groups to improve
maternal/neonatal health were each estimated to
cost more than $100 per DALY averted.63 Cost-
effectiveness of replacing IFA with MMS will be
most favorable in countries with well-performing
IFA distribution programs.
It is also important to note that the cost-
effectiveness analyses undertaken in support of the
task force and reported in this volume ignore pro-
grammatic transition costs and are based exclu-
sively on the differences in IFA and multiple
micronutrient tablet costs, which can be significant.
However, increasing and sustained demand for
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multiple micronutrient tablets will reduce tablet
prices owing to scale economies in production and
in the procurement of multiple micronutrient tablet
ingredients. Future work should expand the tempo-
ral focus of analysis (e.g., to 10 years) and include all
of the transition costs and time lags associated with
switching from IFA to MMS, which will likely vary
by country. Future work should also assess (perhaps
in the context of sensitivity analyses) the effects on
benefits and on costs of consuming fewer than, and
in excess of, the prescribed 180 tablets per preg-
nancy.
Task force conclusions
The task force was convened to reassess the evi-
dence base for antenatal MMS and to help policy-
makers understand under what circumstances and
contexts MMS could be considered under the pro-
vision provided in the WHO ANC guideline stat-
ing that “policymakers in populations with a high
prevalence of nutritional deficiencies might con-
sider the benefits of MMN supplements on mater-
nal health.” To describe these circumstances and
contexts, the group also compiled and evaluated
evidence regarding the prevalence of micronutrient
deficiencies and adverse pregnancy outcomes. The
new evidence confirms that inadequate micronu-
trient intakes, micronutrient deficiencies, adverse
pregnancy outcomes, and infant mortality are still
highly prevalent in LMICs.
Despite the variability in prevalence of micronu-
trient deficiencies among WRA and a general lack
of data on dietary intake and micronutrient status
among pregnant women in most LMICs, there is
clear and consistent evidence from trial data that
MMS may be beneficial in LMICs where micronu-
trient deficiencies are relatively common and would
reduce the risk for preterm birth, SGA, and LBW.
In addition to the overall benefits to pregnant
women and their infants, the IPD subgroup anal-
yses revealed a greater potential to respond to
MMS among anemic women, who had a reduced
risk of LBW (19%), SGA (8%), and 6-month mor-
tality (29%) compared with the IFA group.4 In
addition, female infants born to mothers receiv-
ing MMS had a significant reduction in neona-
tal (15%), 6-month (15%), and infant mortality
(13%) compared with female infants from mothers
receiving IFA. Although results from post-hoc sub-
group analyses should be critically interpreted, the
task force concludes that these results suggest that
MMS might have the potential to further reduce
the risk of these adverse outcomes among these
subgroups.
It is important to note that these risk reductions
for preterm birth, LBW, SGA, and stillbirth asso-
ciated with MMS during pregnancy are in addi-
tion to the benefits provided by IFA supplements
alone.5,64 Additionally, these trials were performed
across diverse settings in LMICs, where micronu-
trient deficiencies and adverse birth outcomes are
relatively common. Thus, the task force concluded
that these trials provide broad applicability to many
settings in LMICs.
A cost-effectiveness analysis was performed on
the basis of the data provided by all trials and
the subset that used equal doses of iron included
in the IPD meta-analysis.62 The cost per mul-
tiple micronutrient tablet will be slightly higher
than that of IFA, and the very large volume of
tablets required to cover all pregnancies will cause
even small differences in the multiple micronutri-
ent supplement versus IFA tablet costs to translate
into large outlays. However, the task force expects
the additional mortality and birth outcome ben-
efits associated with the more expensive multiple
micronutrient tablets to generally result in favorable
cost-effectiveness values when comparedwith other
programs aimed at reducing mortality and unde-
sirable birth outcomes, as described by Engle-Stone
et al.62 In addition, when produced and purchased
at scale, the cost differential between IFA andmulti-
ple micronutrient tablets would be further reduced,
which would further improve the cost-effectiveness
of multiple micronutrient supplementation pro-
grams. That said, the cost-effectiveness of multiple
micronutrient supplementation programswill likely
be reduced in countries in which IFA programs
perform poorly or when considering the country-
specific planning, implementation,monitoring, and
evaluation costs associated with transitioning from
IFA to multiple micronutrient tablets. These addi-
tional costs were not addressed in the analyses con-
sidered by the task force nor were the timeframes
for these transitions considered.
The UNIMMAP formulation was specifically
designed to meet the increased micronutrient
requirements of pregnancy.50 The supplement con-
tains 15 micronutrients at or near the levels needed
during pregnancy, including 30 mg of iron, which
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is within the 30–60 mg of daily iron recommended
by the WHO. Despite the levels of micronutrients
near the RDA or AI, there is little risk of exceed-
ing the UL of micronutrients even when combined
with adequate dietary intake. In addition, the trials
that reported on side effects and adherence showed
no difference in adherence and generally no differ-
ences in reported side effects between MMS and
IFA, suggesting that compliance to these supple-
ments will be similar.4 On the basis of the use of the
UNIMMAP formulation in many of the trials, the
task force concluded that this formulation should
be used for antenatal supplementation with MMS
going forward. There is evidence of greater benefit
when started early in pregnancy and should be con-
tinued for the duration of the pregnancy. In many
contexts, this equates to approximately 6months (or
180 days).
On the basis of this review of evidence, the
task force concluded that the use of a daily MMS
does not increase the risk of adverse effects, has
a number of additional benefits for mortality and
birth outcomes compared with IFA, and can be a
cost-effective intervention for pregnant women in
LMICs, where multiple micronutrient deficiencies
persist. To identify the settings where supplemen-
tation with MMS is most likely to benefit pregnant
women and their infants, the task force suggests
using available biomarker, dietary intake, or diet
diversity data to determine the prevalence of mul-
tiple micronutrient deficiencies or estimate the
likelihood of deficiencies. Other indicators, such
as the prevalence of low maternal BMI, mater-
nal anemia, LBW, SGA, and preterm births, may
also be used as complementary data. Where these
conditions are prevalent, multiple micronutrient
supplementation is likely to lead to additional
benefits as compared with those attributable to IFA
supplementation alone, and could be included as
part of routine ANC to improve maternal micronu-
trient status and to reduce the risks of mortality and
adverse birth outcomes.
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